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INTRODUCTION
Three diisocyanates cause occupational asthma (OA): toluene 
diisocyanate (TDI), 4,4-diphenylmethane diisocyanate (MDI), 
and 1,6-hexamethylene diisocyanate (HDI).
1-3 TDI is the most 
common cause of OA in developing countries, with a prevalence 
of 2.9-13% in exposed workers.
4 The pathogenic mechanisms of 
isocyanate-induced asthma remain incompletely understood
5 
and no reliable method of serological testing has been estab-
lished.
Because permanent impairment of lung function was noted 
in long-term follow-up studies of isocyanate-induced asthma, 
the development of biomarkers to identify susceptible subjects 
among exposed workers is essential. Previously, we reported on 
biomarkers of TDI-induced asthma, but no others have been re-
ported. In this review, we summarize potential biomarkers for 
isocyanate-induced asthma, based on different mechanisms, 
including immunologic, genetic, neurogenic, and protein 
markers.
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IMMUNOLOGIC BIOMARKERS: SERUM SPECIFIC IgE/IgG 
ANTIBODIES
Serum specific IgE and IgG antibodies to TDI-human serum 
albumin (HSA) conjugate were found to have diagnostic val-
ue.
6-8 A leading hypothesis concerning the pathogenesis of TDI-
OA is that TDI acts as a hapten and undergoes nucleophilic ad-
dition reactions (conjugates) in vivo with airway proteins.
9 Sev-
eral groups have detected serum specific IgE antibodies to TDI-
HSA conjugate in the sera of workers with a positive bronchial 
challenge to TDI; the prevalence varied between 0 and 50% of 
workers,
10,11 depending on the conditions used to prepare the 
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Three diisocyanates can cause occupational asthma (OA): toluene diisocyanate (TDI), 4,4 diphenylmethane diisocyanate (MDI), and 1,6-hexameth-
ylene diisocyanate (HDI). We analyzed potential biomarkers of isocyanate-induced OA, based on investigated immunologic, genetic, neurogenic, and 
protein markers, because there is no serological testing method. The prevalence of serum IgG to cytokeratin (CK)18 and CK19 in TDI-OA was signifi-
cantly higher than in controls, although the prevalence of these antibodies was too low for them to be used as biomarkers. Another candidate bio-
marker was serum IgG to tissue transglutaminase (tTG), because the prevalence of serum specific IgG to tTG was significantly higher in patients 
with TDI-OA than in controls. The human leukocyte antigen (HLA) DRB1*1501-DQB1*0602-DPB1*0501 haplotype may be used as a genetic marker 
for TDI-OA in Koreans via enhanced specific IgE sensitization in exposed subjects. The genetic polymorphisms of catenin alpha 3, alpha-T catenin 
(CTNNA3) were significantly associated with TDI-OA. Additionally, examining the neurokinin 2 receptor (NK2R) 7853G>A and 11424 G>A polymor-
phisms, the NK2R 7853GG genotype had higher serum vascular endothelial growth factor (VEGF) levels than the GA or AA genotypes among Korean 
workers exposed to TDI. To identify new serologic markers using a proteomic approach, differentially expressed proteins between subjects with 
MDI-OA and asymptomatic exposed controls in a Korean population showed that the optimal serum cutoff levels were 69.8 ng/mL for ferritin and 
2.5 µg/mL for transferrin. When these two parameters were combined, the sensitivity was 71.4% and the specificity was 85.7%. The serum cyto-
kine matrix metalloproteinase-9 (MMP-9) level is a useful biomarker for identifying cases of TDI-OA among exposed workers. Despite these possi-
ble biomarkers, more effort should be focused on developing early diagnostic biomarkers using a comprehensive approach based on the pathogenic 
mechanisms of isocyanate-induced OA.
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conjugate
12 and the type of TDI-HSA conjugate used.
13 Addition-
ally, TDI-HSA conjugates may undergo changes in their three 
dimensional configuration, resulting in the generation of new 
antigenic epitopes. Thus, we used a vapor TDI-HSA conjugate 
as an antigen, and found the highest sensitivity in comparison 
with the conventional type (44% vs. 17%), as shown in Table 
1.
7,8,10,14 The time interval between the date of blood withdrawal 
for specific IgE testing and the date of last exposure to isocya-
nate can be an issue. Tee et al.
11 reported that the sensitivity of 
serum specific IgE to isocyanate was the highest when blood 
was taken less than 30 days after the last exposure. However, se-
rum specific IgG to isocyanate may persist for several years af-
ter the last exposure to TDI.
15
Regarding MDI-induced asthma, a few studies have measured 
MDI-specific antibodies in small numbers of subjects.
16,17 We 
measured the level of serum specific IgE and IgG in 58 MDI-ex-
posed workers using an enzyme-linked immunosorbent assay 
(ELISA).
18 The levels of these antibodies were significantly high-
er than those of the unexposed controls. The prevalence of spe-
cific IgG antibody to MDI-HSA conjugate was higher (20.7%) 
than that of specific IgE antibody (8.6%), indicating that serum 
specific IgG antibodies to MDI-HSA conjugate may be useful 
for diagnosing MDI-OA in exposed workers (Table 1). However, 
these antibodies had a relatively low prevalence and better bio-
markers should be identified.
In conclusion, the detection of serum specific IgE or IgG is 
helpful for diagnosing isocyanate-induced asthma, although this 
alone is not sensitive enough to serve as a biomarker. However, it 
is certainly useful for confirming isocyanate-specific type I hy-
persensitivity, documenting exposure, and monitoring subclin-
ical conditions. Efforts to generate new volatile isocyanate-al-
bumin conjugates will increase the sensitivity and specificity of 
serum specific antibody tests, which will have potentially great-
er biological relevance as serologic biomarkers.
SERUM AUTOANTIBODIES
Exposure to TDI increases cytokeratin (CK)19 expression in 
human airway epithelial cells, initiating an immune response.
19 
The prevalence of serum IgG to CK18 and CK19 in TDI-OA was 
significantly higher than in other exposed and unexposed con-
trols. The patients with high serum IgG to CK19 had a signifi-
cantly lower PC20 methacholine, indicating that it may be in-
volved in airway inflammation. However, the prevalence of 
these antibodies is not high enough for them to be used as bio-
markers, because the prevalence was less than 25% in TDI-OA 
patients; the differences were significant compared with as-
ymptomatic exposed controls (AECs; Table 1).
5
Another candidate biomarker is serum IgG to tissue transglu-
taminase (tTG), because the prevalence of serum specific IgG 
to tTG was significantly higher in patients with TDI-OA, com-
pared with AECs, those with allergic asthma, and unexposed 
normal controls. Moreover, the patients with TDI-OA with high 
serum IgG to tTG had significantly lower methacholine PC20 
values. TDI exposure could increase tTG activity via reactive ox-
ygen species (ROS) production, which was found to cross-link 
with CK19 on immunoblot analysis, leading to persistent air-
way inflammation in TDI-OA patients.
20 However, the sensitivi-
ty of this antibody as a biomarker is far too low.
GENETIC MARKERS
The reported genetic markers for isocyanate-induced asthma 
are summarized in Table 2. A study performed in a Korean pop-
ulation found that the frequency of HLA DRB1*1501-DQB1* 
0602-DPB1* haplotype was significantly higher in TDI-OA pa-
tients than in AECs or normal controls. DQB1*0402 was signifi-
cantly associated with the presence of serum specific IgE to 
TDI-HSA conjugate. Thus, the HLA DRB1*1501-DQB1*0602-
DPB1*0501 haplotype may be a genetic marker for the develop-
ment of TDI-OA in Koreans via enhanced specific IgE sensitiza-
tion in exposed subjects.
21 A study in a European population 
suggested an association with HLA DQB1*0503 and an inverse 
relationship with HLA-DQB1*0501.
22-24 Despite some inconsis-
tencies with other studies, our study population is the largest 
and is based on homogenous patients with TDI-induced asth-
ma. However, larger cohorts should be studied in other homog-
enous ethnic populations to confirm whether this biomarker is 
useful.
Another study examined susceptibility genetic markers asso-
ciated with the TDI-OA phenotype. First, a genome-wide asso-
ciation study was performed in 84 patients with TDI OA com-
pared with 263 unexposed healthy controls using the Affyme-
Table 1. Sensitivity and specificity of immunologic markers and autoantibodies 









Specific IgE to TDI-HSA conjugates
Liquid 7.60  99.4  83.3  73.2 
Vapor-80%V* 43.9  95.8  80.5  81.2 
Specific IgG to TDI-HSA conjugates
Liquid 16.7 94.6  55.0  74.2 
Vapor-80%V* 30.3 90.4  89.5  76.7
Specific IgE to MDI-HSA conjugates 28.6 94.1 40.0 90.5
Specific IgG to MDI-HSA conjugates 57.1 84.3 33.4 94.0
IgG  to CK18 26.2 93.5 76.3 60.7
IgG to CK19 26.2 93.5 76.4 62.9
*TDI-albumin conjugates were prepared with an 80/20 isomer mixture of   
2,4/2,6-TDI.
PPV, positive predictive value; NPV, negative predictive value; TDI-HSA, toluene 
diisocyanate–human serum albumin; MDI-HSA, 4, 4-diphenylmethane diisocy-
anate-human serum albumin; CK, cytokeratin.Biomarkers for Isocyanate-Induced Asthma AAIR 
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trix 500K SNP chip. The genetic polymorphisms of catenin al-
pha 3, alpha-T catenin (CTNNA3) were significantly associated 
with TDI-OA. Carriers with the minor haplotype, HT2 [GG], of 
two genetic polymorphisms (rs10762058 and rs7088181) had 
significantly lower PC20 methacholine levels and lower mRNA 
expression of CTNNA3 than non-carriers. A genetic polymor-
phism in the 3’-downstream region of CTNNA3 (rs1786929) 
was significantly associated with the TDI-OA phenotype and 
the prevalence of serum specific IgG to CK19.
25 The small sam-
ple size for genome-wide association is one limitation of this 
study. Nevertheless, as TDI-OA is quite rare in developed coun-
tries, this study should be replicated in other populations. Fur-
thermore, the detailed functions of this gene remain to be de-
termined. In conclusion, this study provides an important con-
tribution for Asian populations by identifying CTNNA3 as a po-
tential biomarker for predicting genetic susceptibility to TDI-in-
duced asthma.
Additionally, a study of a Korean population examined two 
single nucleotide polymorphisms (SNPs) of the neurokinin 2 
receptor: NK2R 7853G>A (Gly231Glu) and 11424 G>A (Ar-
g375His). No significant difference in allele, genotype, or haplo-
type frequencies of these two SNPs was seen, but subjects with 
the NK2R 7853GG genotype had higher serum vascular endo-
thelial growth factor (VEGF) levels than those with GA or AA 
among the TDI-exposed workers, suggesting that the NK2R 
7853GG genotype contributes to increased serum VEGF levels, 
resulting in airway inflammation after TDI exposure, which may 
be mediated by neurogenic ROS.
26 These results suggest that 
the NK2R 7853G>A polymorphism is a candidate biomarker for 
TDI OA. However, this study needs to be repeated using larger 
cohorts. Additionally, the indirect relationship between serum 
VEGF and NK2R 7853G>A needs to be investigated to deter-
mine whether there is a functional association between the two, 
which could assist in determining whether this may be used as a 
biomarker.
Several studies have focused on anti-oxidant gene markers. 
Wikman et al.
27 showed an association of N-acetyltransferase 
genotypes as modifiers of the diisocyanate exposure-associat-
ed asthma risk. They showed that slow acetylator N-acetyltrans-
ferase 1 (NAT1) genotypes had a 2.5-fold greater risk of diisocy-
anate-induced asthma. This was the first result to suggest that 
glutathione S-transferases (GSTs) and NATs play an important 
role in the inception of asthmatic reactions related to occupa-
tional exposure to diisocyanates. A study in a Swedish popula-
tion showed that the glutathione S-transferase pi (GSTP1) gen-
otype should be considered when evaluating biomarkers of TDI 
exposure in urine and plasma. A protective effect of GSTP1 105 
Val was seen in TDI-related asthma.
28 As this study has not been 
replicated, no conclusion can yet be drawn regarding these bio-
markers.
More recently, our unpublished data showed that the adren-
ergic beta-2, ADRB2 46A>G, 252G>A, and 523C>A SNPs and 
haplotype 1 [TTACGC] were significantly associated with spe-
cific IgE antibodies to the TDI-HSA conjugate in TDI-exposed 
subjects. Exposed workers with the AA genotype of the 46 A>G 
polymorphism had significantly higher serum specific IgE lev-
els than those with the GG genotype, suggesting that ADRB2 
polymorphisms may affect IgE-specific sensitization to TDI-
HSA conjugate in TDI exposed workers. As TDI-OA is a complex 
process, ADRB2 polymorphisms with further environmental or 
Table 2. Genetic and protein biomarkers for isocyanate-induced asthma
Gene Full name Genotype Association Population
Genetic biomarkers  
HLA Human leukocyte antigen DRB1*1501-DQB1*0602-DPB1* Yes Korean
HLA Human leukocyte antigen DQB1*0503 Yes European
HLA Human leukocyte antigen DQB1*05 Yes Swedish
HLA Human leukocyte antigen DQB1*0501 No European
CTNNA3 Catenin alpha 3, alpha-T catenin HT2 [GG] Yes Korean
NK2R Neurokinin2 receptor 7853G>A, 11424G>A Yes Korean
NAT1 N-acetyl transferase Slow acetylator Yes Finnish
GSTP1 Glutathione S-transferase pi 105 Val (protective) Yes Swedish
Protein biomarkers
Cutoffs Sensitivity (%) Specificity (%) AUC (95% CI) P value
Ferritin < 69.84 ng/mL 85.71 71.48 0.786 0.053
Transferrin > 2.48 µg/mL 71.43 51.02 0.612 0.4
Ferritin < 69.84 ng/mL and 71.43 85.71 0.786 0.02
transferrin > 2.48 µg/mL
AUC, area under curve.Palikhe et al.
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genetic factors may increase TDI-OA susceptibility and should 
be evaluated further.
PROTEIN MARKERS
Bronchoalveolar lavage (BAL) fluid and plasma are sources of 
proteins. To identify new serologic markers using a proteomic 
approach, differentially expressed proteins between subjects 
with MDI-OA and AECs were studied in a Korean population. 
Two-dimensional electrophoresis was performed using BAL flu-
id obtained from subjects after an MDI-specific inhalation chal-
lenge and selected protein spots were then identified by matrix-
assisted laser desorption/ionization time-of-flight mass spec-
trometry. In total, 23 protein spots distinguished the subjects 
with MDI-OA from AECs. Among them, ferritin expression was 
down-regulated, whereas transferrin expression was up-regu-
lated in subjects with MDI-OA, compared with AECs. The clini-
cal relevance of the differentially expressed spots was evaluated 
by ELISA using sera from the MDI-OA, AEC, and unexposed 
healthy control groups. Then, receiver operating characteristic 
(ROC) curves were plotted, and the sensitivity and specificity 
were determined. To identify subjects with MDI-OA, the opti-
mal serum cutoff levels were 69.8 ng/mL for ferritin and 2.5 µg/
mL for transferrin. When these two parameters were combined, 
the sensitivity was 71.4% and the specificity was 85.7% (Table 2). 
Serum ferritin and transferrin levels are associated with the 
MDI-OA phenotype.
29 However, a recent study performed in 
Spain showed that the serum ferritin and transferrin levels did 
not differ among TDI-OA, TDI-exposed workers without OA, or 
healthy controls; therefore, these potential markers need to be 
studied further before they can be used.
30 Another candidate 
protein as a serologic marker for detecting isocyanate-OA among 
isocyanate-exposed workers was the serum vitamin D binding 
protein (VDBP) level.
31 To confirm this, additional functional 
studies are ongoing.
SERUM CYTOKINES MAY BE BIOMARKERS FOR TDI-OA
The inflammatory response involves lymphocytes, eosino-
phils, neutrophils, and bronchial epithelial cells, and related cy-
tokines, such as myeloperoxidase (MPO) and interleukin-8 (IL-
8), are involved in the pathogenesis of TDI-OA.
32 In particular, 
increased production of matrix metalloproteinase-9 (MMP-9), 
tissue inhibitor of metalloproteinase-1 (TIMP-1),
33,34 and VEGF 
35 
are thought to play important roles in airway inflammation and 
airway remodeling.
Recent studies have revealed that MMP-9 acts on pro-inflam-
matory cytokines, chemokines, and other proteins to regulate 
varied aspects of inflammation.
36,37 A longitudinal study of pa-
tients with diisocyanate-induced asthma showed that inhaled 
steroid medication increased the BAL levels of MMP-9 and 
MMP-9/TIMP-1, which were inversely correlated with Th-2 type 
inflammation, suggesting a protective role of MMP-9.
38 To eval-
uate the clinical significance of these cytokines, we compared 
the serum cytokine levels in patients with TDI-OA and AECs at 
the time of diagnosis and found significant differences in the 
serum levels of MMP-9, IL-8, and VEGF.
39 Of these, MMP-9 was 
the most prominent cytokine, with the highest sensitivity (79.7%) 
and specificity (80.8%) using specific cutoff values. When the 
cytokines were combined to improve the sensitivity and speci-
ficity, the combination of MMP-9, VEGF, and IL-8 was the best, 
with the area under curve (AUC) value increasing to 0.822 (95% 
CI, 0.752 0.894; P<0.001) and the sensitivity and specificity 
changing to 82.6% and 75.8%, respectively. Considering the cost-
benefit ratio and its applicability in clinical practice, MMP-9 
can be considered the best serologic marker for predicting TDI-
OA among TDI-exposed workers.
CONCLUSION
We have identified several potential candidate biomarkers in 
isocyanate-induced asthma, including serum specific IgE/IgG 
antibodies to TDI-HSA conjugates, serum specific IgG to CK19 
and TG, genetic biomarkers, such as HLA DRB1*1501-DQB1* 
0602-DPB1*0501 haplotype, and serum levels of VDBP and 
MMP-9 for TDI-OA. In MDI-OA, serum-specific IgG antibody, 
ferritin and transferritin levels may be used as serologic mark-
ers. Despite these possible biomarkers, more effort should be 
focused on developing early diagnostic biomarkers, based on a 
comprehensive approach and the pathogenic mechanisms of 
isocyanate-induced OA. Because the identification of asymp-
tomatic sensitizers and occupational rhinitis are important and 
are risk factors for OA, a surveillance system using biomarkers 
should be initiated for screening susceptible workers.
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